Browsing: Redefining

The management of ocular malignancies has historically straddled a fine line between ophthalmology and systemic oncology, occasionally falling into institutional…

In this episode of Oncology On the Go, CancerNetwork® joined Matthew Matasar, MD, chief of the Division of Blood Disorders…

Dr. Ajai Chari and Dr. Rahul Banerjee discuss how the management of relapsed/refractory multiple myeloma (RRMM) is evolving as newer…

In this segment, the discussion returns to the theme of long term management in EGFR mutated metastatic non-small cell lung…

In 1983, the internet as we know it today and its commercial-use capacity were born.1 Occurring just 4 years before…

The findings from the phase 3 PSMAddition trial (NCT04720157) are poised to further diversify the treatment landscape for metastatic hormone-sensitive…

Following the 2026 Tandem Meeting, Yan Leyfman, MD, a fellow at NewYork-Presbyterian Hospital and a hematologic malignancies board member for…

For clinicians treating undifferentiated pleomorphic sarcoma (UPS), the integration of immune checkpoint inhibitors remains one of the most debated paths…

The term “patient-centered care” is often treated as a staple of clinical mission statements, yet in the high-volume, high-tech environment…

The PRECEDE Consortium provides a standardized, large-scale infrastructure for the early detection of pancreatic cancer, addressing a clinical landscape where…